1. Introduction
===============

Since the first reported isolation of a diketopiperazine (DKP) from the sponge *Dysidea herbacea* \[[@b1-marinedrugs-09-02469]\], there have been several reports describing the isolation of this class of compound from other marine sponges \[[@b2-marinedrugs-09-02469]--[@b4-marinedrugs-09-02469]\]. DKPs are also reported from marine microbial sources \[[@b5-marinedrugs-09-02469]--[@b8-marinedrugs-09-02469]\], including the proteobacteria *Alcaligenes faecalis*, isolated from the sponge *Stelletta tenuis* \[[@b9-marinedrugs-09-02469]\]. The metabolites reported in these investigations are mostly the products of 4-hydroxy-proline \[[@b2-marinedrugs-09-02469],[@b5-marinedrugs-09-02469],[@b6-marinedrugs-09-02469],[@b8-marinedrugs-09-02469]\] or proline \[[@b7-marinedrugs-09-02469]\] reacting with phenylalanine \[[@b2-marinedrugs-09-02469],[@b5-marinedrugs-09-02469]\], arginine \[[@b4-marinedrugs-09-02469]\], leucine \[[@b5-marinedrugs-09-02469]--[@b7-marinedrugs-09-02469]\], isoleucine \[[@b7-marinedrugs-09-02469]\], norvaline \[[@b3-marinedrugs-09-02469]\] or alanine \[[@b8-marinedrugs-09-02469]\].

Sponges from the genus *Stelletta* are known to produce a number of other bioactive classes of compounds, including but not limited to steroids \[[@b10-marinedrugs-09-02469]\], alkaloids \[[@b11-marinedrugs-09-02469],[@b12-marinedrugs-09-02469]\], isomalabaricane triterpenes \[[@b13-marinedrugs-09-02469]\], acetylenic acids \[[@b14-marinedrugs-09-02469]\] and lysophosphatidylcholines \[[@b15-marinedrugs-09-02469]\]. Initial interest in the methanol (MeOH) extract of the sponge *Stelletta* sp. was motivated by to its potent activity in the NCI 60 cell line screen and a unique COMPARE analysis profile (average GI~50~ 0.5 μg/mL) \[[@b16-marinedrugs-09-02469]\]. This profile was different to that of the standard chemotherapeutic agents paclitaxel, cisplatin, gemcitadine, bryostatin 1, didemnin B, tamoxifen and vinblastine (data provided by NCI). Subsequent bioassay-guided investigations of this extract led to the isolation of a new DKP cyclo-(4-*S*-hydroxy-*R*-proline- *R*-isoleucine) (**1**), the previously reported bengamides; A (**2**) \[[@b17-marinedrugs-09-02469]\], F (**3**) \[[@b18-marinedrugs-09-02469]\], N (**4**) \[[@b19-marinedrugs-09-02469]\], Y (**5**) \[[@b20-marinedrugs-09-02469]\], and the previously reported bengazoles; Z (**6**) \[[@b20-marinedrugs-09-02469]\], C~4~ (**7**) \[[@b21-marinedrugs-09-02469]\] and C~6~ (**8**) \[[@b21-marinedrugs-09-02469]\]. Described in this publication is the isolation and structure elucidation of **1**, together with the activity of compounds **1**--**8**.

2. Results and Discussion
=========================

The DKP cyclo-(4-*S*-hydroxy-*R*-proline-*R*-isoleucine) **1** was isolated and the molecular formula C~11~H~18~N~2~O~3~, corresponding to four double-bond equivalents, was determined by (+)-ESI-FTMS accurate mass measurement. The ^13^C NMR data of **1** contained resonances consistent with the presence of two amide carbonyl groups (δ~C~ 170.5 (C-7), 165.4 (C-1)) as the only multiple bonds within the molecule, and a hydroxy methine (δ~C~ 66.8 (C-4); δ~H~ 4.28, 1H, dd, *J =* 4.6, 4.6 Hz) ([Table 1](#t1-marinedrugs-09-02469){ref-type="table"}). These functionalities accounted for all of the oxygen and nitrogen atoms and all of the multiple bonds in **1**, indicating the molecule to be bicyclic. Analysis of the COSY NMR data of **1** showed an extended ^1^H--^1^H spin system from H-9 to H~3~-12 via H-10 and H-11, as well as a vicinal COSY NMR correlation from H-10 to H~3~-13. Observed gHMBC NMR correlations from δ~H~ 7.97 to the ^13^C NMR resonances at δ~C~ 59.1 (C-9), δ~C~ 56.7 (C-6), δ~C~ 34.8 (C-10) and C-1 positioned this hydrogen at N-8. Further gHMBC NMR correlations from δ~H~ 4.00 (H-9) to δ~C~ 23.9 (C-11) and δ~C~ 14.9 (C-13), as well as to C-1 and C-10, clearly positioned H-9 adjacent to the C-1 carbonyl and N-8, giving rise to an isoleucine moiety (**1A**). Additional gHMBC NMR correlations from 8-N[H]{.ul} and H-9 to C-7 revealed it was attached to N-8. A further contiguous ^1^H--^1^H spin system from H-6 to H~2~-3, in addition to gHMBC NMR correlations from the 8-N[H]{.ul} and H~b~-3 to C-6, and from H~b~-3 to C-1 established the remaining nitrogen (N-2) to be attached to C-1, C-6 and C-3, giving rise to the two rings within **1**. The planar structure of **1** is as shown ([Scheme 1](#f2-marinedrugs-09-02469){ref-type="fig"}).

The configuration at C-4, C-6 and C-9 of **1** was established through analysis of ^1^H--^1^H coupling constants, optical rotation measurement, molecular minimisations and comparison with literature compounds \[[@b3-marinedrugs-09-02469],[@b6-marinedrugs-09-02469],[@b7-marinedrugs-09-02469]\]. The magnitude of the coupling constants associated with H-6 (dd, *J* = 11.0, 6.1 Hz) and the observed COSY NMR correlations between H-6 and H~a/b~-5 established it to have a pseudo-axial orientation, similar to that of cyclo\[[l]{.smallcaps}-(4-hydroxyprolinyl)-[l]{.smallcaps}-leucine)\] (H-6, dd, *J* = 11.1, 6.1 Hz) \[[@b6-marinedrugs-09-02469]\]. An apparent zero coupling between H-4 (*J* = 4.6, 4.6 Hz) and H~b~-3 or H~a~-5 as evident by lack of observed COSY NMR correlations, and observed couplings to H~a~-3 (*J* = 12.5, 4.6 Hz) and H~b~-5 (*J* = 12.9, 11.0, 4.6 Hz), was indicative of H-4 being orientated at approximately 90° to both H~b~-3 and H~a~-5. The observed weak COSY NMR correlation between 8-N[H]{.ul} and H-9, and the broad singlet for H-9 (similar to that observed in cyclo-\[*S*-proline-*S*-isoleucine)\] \[[@b3-marinedrugs-09-02469]\]), revealed H-9 to be axial. Molecular modelling studies showed that the observed coupling constants were in agreement with either *R*,*R* ([Figure 1](#f1-marinedrugs-09-02469){ref-type="fig"}) or *S*,*S* configuration at C-6/C-9 but definitely not *R*,*S* or *S*,*R* ([Supplementary Data S6-S13 and Table S1](#s1-marinedrugs-09-02469){ref-type="supplementary-material"}). Based on optical rotation trends of DKPs from the literature \[[@b3-marinedrugs-09-02469],[@b7-marinedrugs-09-02469]\], the overall positive \[α\]^21^~D~ = +12° indicated the absolute configuration at C-6 should be *R*, therefore supporting the *R*,*R* configuration. The magnitude of the optical rotation is also in agreement with other C-4 hydroxylated DKPs \[[@b5-marinedrugs-09-02469],[@b7-marinedrugs-09-02469]\]. The molecular model shown in [Figure 1](#f1-marinedrugs-09-02469){ref-type="fig"}, with calculated dihedral angles for H~a~-5--C-5--C-6--H-6 (Φ = 41°), H~b~-5--C-5--C-6--H-6 (Φ = 163°), H-4--C-4--C-5--H~a~-5 (Φ = 79°), H-4--C-4--C-5--H~b~-5 (Φ = −42°), H~a~-3--C-3--C-4--H-4 (Φ = 29°), H~b~-3--C-3--C-4--H-4 (Φ = −93°) and 8-N[H]{.ul}--N-8--C-9--H-9 (Φ = 91°), best explained the observed COSY NMR correlations, ^1^H--^1^H coupling constants and the positive sign of \[α\]^21^~D~ confirmed the absolute configuration at C-3, C-6 and C-8 to be as shown. It is likely that this DKP was produced by an enzymatically controlled condensation reaction between [d]{.smallcaps}-isoleucine and 4-*S*-hydroxy-[d]{.smallcaps}-proline ([Scheme 1](#f2-marinedrugs-09-02469){ref-type="fig"}) \[[@b22-marinedrugs-09-02469]\].

The cytotoxicity of **1**--**8** was investigated against the human tumour cell lines H460, SF-268, MCF-7, HT-29 and a normal mammalian cell line CHO-K1. The DKP **1** exhibited minimal activity towards MCF-7, H460 and HT-29 cells and no activity towards SF-268 or CHO-K1 cells at the highest dose ([Table 2](#t2-marinedrugs-09-02469){ref-type="table"}). In contrast, the GI~50~ values (μM) for bengamides A (**2**), F (**3**), N (**4**), Y(**5**), and bengazoles Z (**6**), C~4~ (**7**) and C~6~ (**8**) were comparable to those reported in previous studies \[[@b19-marinedrugs-09-02469],[@b20-marinedrugs-09-02469]\], and accounted for the activity observed in the original MeOH extract.

3. Experimental
===============

3.1. General Experimental Procedures
------------------------------------

General experimental details have been described previously \[[@b29-marinedrugs-09-02469]\].

3.2. Animal Material
--------------------

This specimen of the sponge *Stelletta* sp., (Family Ancorinidae) was collected from the west side of Jamieson Reef, Bonaparte Archipelago, North West Western Australia, at depths ranging from 16 m to 20 m, in August 1991. A voucher specimen (Accession number QMG312281) has been lodged with the Queensland Museum.

3.3. Bioassay
-------------

Cellular bioassays were undertaken as previously described \[[@b19-marinedrugs-09-02469]\].

3.4. Extraction and Isolation
-----------------------------

Freeze dried sponge material (125 g dry weight) was extracted sequentially with dichloromethane (CH~2~Cl~2~), MeOH and H~2~O; activity was confined to the CH~2~Cl~2~ and MeOH fractions. The MeOH fraction was subjected to reversed phase C18 flash vacuum chromatography (RP-C18, 40%, 60%, 80%, 100% MeOH in H~2~O, and 100% CH~2~Cl~2~) with activity located in the 40% and 100% MeOH fractions. The 100% MeOH fraction was further separated using RP HPLC (4 mL/min, gradient elution from 60% acetonitrile (CH~3~CN):H~2~O (+0.1% formic acid \[HCO~2~H\]) to 100% CH~3~CN (+0.1% HCO~2~H) over 10 min, then isocratic 100% CH~3~CN (+0.1% HCO~2~H) for 15 min through a 150 mm × 10 mm 5 μ Phenomenex Luna C18 column), to give thirteen fractions. The first active fraction, fraction 1, was subjected to RP HPLC (4 mL/min, gradient elution from 20% CH~3~CN:H~2~O (+0.1% HCO~2~H) to 100% CH~3~CN (+0.1% HCO~2~H) over 20 min through a 150 × 10 mm 5 μ Phenomenex Luna Phenyl-Hexyl column) to yield bengamide Y (**5**) (0.8 mg, 0.0006%). The additional active fractions 3 and 4 were both partitioned with *n*-hexane and MeOH (1:1) to yield bengamides N (**4**) (1.4 mg, 0.001%) and A (**2**) (3.3 mg 0.003%), respectively.

The 40% MeOH fraction was subjected to further RP-C18 (10%, 20%, 30%, 40%, 50% and 100% MeOH in H~2~O) and the active fractions (30% and 40% MeOH) fractionated on RP HPLC (4 mL/min, gradient elution from 10% CH~3~CN:H~2~O (+0.1% HCO~2~H) to 64% CH~3~CN:H~2~O (+0.1% HCO~2~H) over 12 min, then isocratic 100% CH~3~CN (+0.1% formic acid) for an additional 5 min through a 150 mm × 10 mm 5 μ Phenomenex Luna C18 column) to yield bengamide F (**3**, 2.1 mg, 0.002%), bengazoles Z (**6**, 5.0 mg, 0.004%), C~4~ (**7**) (13.8 mg, 0.011%) and C~6~ (**8**) (23.6 mg, 0.012%) and the new DKP cyclo-(4-*S*-hydroxy-*R*-proline-*R*-isoleucine) **1** (1.5 mg, 0.001%).

### 3.4.1. Cyclo-(4-*S*-hydroxy-*R*-proline-*R*-isoleucine) (**1**)

Isolated as a colourless oil. \[α\]^21^~D~ +12° (*c* 0.025, CHCl~3~); IR (film) *ν*~max~ 3391, 1649 cm^−1^; UV (PDA, CH~3~CN/H~2~O) λ~max~ 220 nm; ^1^H (600 MHz, *d*~6~-DMSO) and ^13^C (150 MHz, *d*~6~-DMSO) NMR data see [Table 1](#t1-marinedrugs-09-02469){ref-type="table"}; ESI-FTMS \[M + Na\]^+^ 249.1203 (calcd. for C~11~H~18~N~2~O~3~Na 249.1215).

### 3.4.2. Bengamide A (**2**)

Isolated as a colourless oil. ^1^H NMR and ^13^C NMR spectral data were consistent with published values \[[@b17-marinedrugs-09-02469]\].

### 3.4.3. Bengamide F (**3**)

Isolated as a colourless oil. ^1^H NMR and ^13^C NMR spectral data were consistent with published values \[[@b18-marinedrugs-09-02469]\].

### 3.4.4. Bengamide N (**4**)

Isolated as a colourless oil. ^1^H NMR and ^13^C NMR spectral data were consistent with published values \[[@b19-marinedrugs-09-02469]\].

### 3.4.5. Bengamide Y (**5**)

Isolated as a colourless oil. ^1^H NMR and ^13^C NMR spectral data were consistent with published values \[[@b20-marinedrugs-09-02469]\].

### 3.4.6. Bengazole Z (**6**)

Isolated as a colourless oil. ^1^H NMR and ^13^C NMR spectral data were consistent with published values \[[@b20-marinedrugs-09-02469]\].

### 3.4.7. Bengazole C~4~ (**7**)

Isolated as a colourless oil. ^1^H NMR and ^13^C NMR spectral data were consistent with published values \[[@b21-marinedrugs-09-02469]\].

### 3.4.8. Bengazole C~6~ (**8**)

Isolated as a colourless oil. ^1^H NMR and ^13^C NMR spectral data were consistent with published values \[[@b21-marinedrugs-09-02469]\].

4. Conclusion
=============

The DKP cyclo-(4-*S*-hydroxy-*R*-proline-*R*-isoleucine) (**1**), together with the known bengamides; A (**2**), F (**3**), N (**4**), Y (**5**), and bengazoles; Z (**6**), C~4~ (**7**) and C~6~ (**8**), was isolated from the Australian marine sponge *Stelletta* sp. Interestingly, this is the first report of bengamides or bengazoles from the genus *Stelletta*, however, it should be noted that they have previously been reported from species of *Dorypleres splendens* \[[@b24-marinedrugs-09-02469]\], which has since been reclassified as *Jaspis splendens*, and from *Jaspis* sp. \[[@b24-marinedrugs-09-02469]\], both of which belong to the Ancorinidae family of sponges. The cyclo-(4-*S*-hydroxy-*R*-proline-*R*-isoleucine) (**1**) was not cytotoxic against the cell lines MCF-7, H460, HT-29, SF-268 or CHO-K1. The DKP class of compounds has recently gained interest in drug discovery \[[@b25-marinedrugs-09-02469]\] due to their chiral, rigid and functionalised structures. These features enable them to bind to a large variety of receptors with high affinity giving rise to a broad range of biological activities, including cytotoxicity, quorum sensing, antibacterial, antifungal, antiviral, antiprion, antitumor, and immunosuppressive functions, even plant-growth regulators \[[@b7-marinedrugs-09-02469],[@b26-marinedrugs-09-02469]--[@b28-marinedrugs-09-02469]\]. Our report adds to the vast knowledge of these potentially therapeutic molecules.
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![Minimum energy conformation of **1** obtained from MM2 calculations without applying any dihedral angle constraints \[[@b23-marinedrugs-09-02469]\]. The calculated dihedral angles for H~b~-3--C-3-- C-4--H-4 (−93°), H-4--C-4--C-4--H~a~-5 (79°) and for 8-N[H]{.ul}--N-8--C-9--H-9 (91°), all which approximate 90° as observed experimentally from the ^1^H--^1^H coupling constants, are indicative of the absolute configurations at C-4 as being *S* and at both C-6 and C-9 being *R*.](marinedrugs-09-02469f1){#f1-marinedrugs-09-02469}

![Structures of the bengazoles, bengamides and **1** isolated from *Stelletta* sp. and the proposed enzymatically controlled condensation reaction between D-isoleucine and 4-*S*-hydroxy-[d]{.smallcaps}-proline to yield **1**.](marinedrugs-09-02469f2){#f2-marinedrugs-09-02469}

###### 

NMR data for **1** (600 MHz, *d*~6~-DMSO), cyclo-\[*S*-proline-*S*-isoleucine)\] (300 MHz, CDCl~3~) and ^1^H NMR data for cyclo\[[l]{.smallcaps}-(4-hydroxyprolinyl)-[l]{.smallcaps}-leucine)\] (300 MHz, CD~3~OD).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.           ^13^C δ (m)   ^1^H δ (m, *J* Hz)                COSY                     gHMBC                        ^1^H δ (m, *J* Hz) of cyclo-\[*S*-proline-*S*-isoleucine)\] \[[@b3-marinedrugs-09-02469]\]   ^1^H δ (m, *J* Hz) of cyclo\[[l]{.smallcaps}-(4-hydroxyprolinyl)-[l]{.smallcaps}-leucine)\] \[[@b6-marinedrugs-09-02469]\]
  ------------- ------------- --------------------------------- ------------------------ ---------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  1             165.4 (s)                                                                                                                                                                                          

  2                                                                                                                                                                                                                

  3             53.8 (t)      3.51 (1H, dd, 12.5, 4.6)\         H~b~-3, H-4\             C-1, C-4, C-5, C-6\          3.6--3.5 (2H, m)                                                                             3.65 (1H, dd, 12.5, 4.3)\
                              3.20 (1H, d, 12.5)                H~a~-3                   C-1, C-4, C-5, C-6                                                                                                        3.42 (1H, d, 12.5)

  4             66.8 (d)      4.28 (1H, br dd, 4.6, 4.6)        H~a~-3, 4-OH, H~b~-5     C-3, C-6                     2.0--1.9 (1H, m)\                                                                            4.28 (1H, t, 4.3)
                                                                                                                      1.9--1.8 (1H, m)                                                                             

  4-O[H]{.ul}                 5.10 (O[H]{.ul}, br s,)           H-4                                                   \-                                                                                           \-

  5             37.2 (t)      2.03 (1H, dd, 12.9, 6.1)\         H~b~-5, H-6\             C-3, C-4\                    2.3--2.2 (1H, m)\                                                                            2.27 (1H, dd, 13.3, 6.5)\
                              1.88 (1H, ddd, 12.9, 11.0, 4.6)   H-4, H~a~-5, H-6         C-4, C-6, C-7                2.1--2.0 (1H, m)                                                                             2.08 (1H, ddd, 13.3, 11.1, 4.3)

  6             56.7 (d)      4.31 (1H, dd, 11.0, 6.1)          H~2~-5                   C-5, C-7                     4.07 (1H, t, 7.5)                                                                            4.51 (1H, dd, 11.1, 6.5)

  7             170.5 (s)                                                                                                                                                                                          

  8-N[H]{.ul}                 7.97 (1[H]{.ul}, s)               H-9                      C-1, C-6, C-7, C-9, C-10     5.99 (1H, br s)                                                                              exchangeable

  9             59.1 (d)      4.00 (1H, br s)                   8-N[H]{.ul} (w), H-10    C-1, C-7, C-10, C-11, C-13   3.96 (1H, br s)                                                                              4.15 (1H, m)

  10            34.8 (d)      2.01 (1H, m)                      H-9, H~b~-11, H~3~-13    C-1, C-13, C-11              2.4--2.3 (1H, m)                                                                             1.90 (1H, m)\
                                                                                                                                                                                                                   1.50 (1H, dd, 8.0)

  11            23.9 (t)      1.32 (1H, qdd, 11.8, 7.4, 4.5)\   H~b~-11, H~3~-12\        C-9, C-10, C-12, C-13\       1.5--1.4 (1H, m)\                                                                            1.88 (1H, m)
                              1.26 (1H, qdd, 11.8, 9.2, 7.2)    H-10, H~a~-11, H~3~-12   C-9, C-10, C-12, C-13        1.3--1.1 (1H, m)                                                                             

  12            12.3 (q)      0.82 (3H, t, 7.4)                 H~2~-11                  C-10, C-11                   0.92 (3H, t, 7.4)                                                                            0.95 (3H, d, 6.4)

  13            14.9 (q)      0.97 (3H, d, 7.0)                 H-10                     C-9, C-10, C-11              1.05 (3H, d, 7.2)                                                                            0.96 (3H, d, 6.4)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

GI~50~ (μM) data for compounds **1**--**8** against SF-268, MCF-7, H460, HT-29 and CHO-K1.

  No.     SF-268 [a](#tfn1-marinedrugs-09-02469){ref-type="table-fn"}   MCF-7 [b](#tfn2-marinedrugs-09-02469){ref-type="table-fn"}   H460 [c](#tfn3-marinedrugs-09-02469){ref-type="table-fn"}   HT-29 [d](#tfn4-marinedrugs-09-02469){ref-type="table-fn"}   CHO-K1 [e](#tfn5-marinedrugs-09-02469){ref-type="table-fn"}
  ------- ------------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------
  **1**   \>295                                                         204                                                          234                                                         270                                                          \>295
  **2**   \<0.02                                                        \<0.02                                                       \<0.02                                                      \<0.02                                                       0.1
  **3**   1.8                                                           0.7                                                          0.6                                                         1.5                                                          32
  **4**   \<0.02                                                        \<0.02                                                       \<0.02                                                      \<0.02                                                       0.2
  **5**   72                                                            52                                                           25                                                          48                                                           \>184
  **6**   22                                                            18                                                           8                                                           13                                                           94
  **7**   0.3                                                           0.8                                                          0.1                                                         0.6                                                          1.2
  **8**   0.02                                                          0.06                                                         \<0.02                                                      0.1                                                          0.8

SF-268 Central nervous system-glioblastoma cells;

MCF-7 Breast-pleural effusion adenocarcinoma cells;

H460 Lung-large cell carcinoma cells;

HT-29 Colon-recto-sigmoid colon adenocarcinoma cells;

CHO-K1 Sub-clone of Chinese hamster ovary cells.
